11,660 Shares of Spyre Therapeutics, Inc. $SYRE Purchased by New York Life Investment Management LLC

New York Life Investment Management LLC purchased a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE – Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 11,660 shares of the company’s stock, valued at approximately $1,038,000.

A number of other hedge funds have also modified their holdings of SYRE. Bank of America Corp DE boosted its stake in Spyre Therapeutics by 192.6% during the 1st quarter. Bank of America Corp DE now owns 1,228,093 shares of the company’s stock worth $61,945,000 after acquiring an additional 808,366 shares during the last quarter. Perceptive Advisors LLC grew its holdings in Spyre Therapeutics by 23.3% during the first quarter. Perceptive Advisors LLC now owns 3,783,225 shares of the company’s stock valued at $190,826,000 after purchasing an additional 714,000 shares during the period. Assenagon Asset Management S.A. bought a new stake in Spyre Therapeutics in the third quarter valued at approximately $53,349,000. ADAR1 Capital Management LLC increased its stake in Spyre Therapeutics by 893.6% in the first quarter. ADAR1 Capital Management LLC now owns 338,323 shares of the company’s stock valued at $17,065,000 after purchasing an additional 304,272 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in Spyre Therapeutics in the second quarter valued at approximately $21,768,000. 80.39% of the stock is currently owned by institutional investors and hedge funds.

Spyre Therapeutics Stock Performance

Shares of SYRE stock opened at $104.00 on Monday. The company has a market capitalization of $9.88 billion, a P/E ratio of -37.96 and a beta of 3.24. The company’s 50 day moving average price is $91.48 and its two-hundred day moving average price is $76.31. Spyre Therapeutics, Inc. has a 52 week low of $22.13 and a 52 week high of $110.64.

Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.12). Analysts forecast that Spyre Therapeutics, Inc. will post -2.78 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on SYRE. Wall Street Zen cut shares of Spyre Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 31st. Deutsche Bank decreased their price target on shares of Spyre Therapeutics from $135.00 to $127.00 and set a “buy” rating for the company in a report on Wednesday, August 26th. JPMorgan Chase & Co. began coverage on shares of Spyre Therapeutics in a research report on Thursday, October 1st. They issued an “overweight” rating and a $110.00 price objective for the company. Guggenheim raised their price objective on Spyre Therapeutics from $130.00 to $135.00 and gave the stock a “buy” rating in a research note on Wednesday, November 4th. Finally, UBS Group began coverage on Spyre Therapeutics in a report on Sunday, October 11th. They set a “buy” rating and a $120.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $110.53.

Read Our Latest Stock Analysis on Spyre Therapeutics

Insider Activity at Spyre Therapeutics

In related news, CEO Cameron Turtle sold 15,000 shares of the company’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $92.01, for a total value of $1,380,150.00. Following the completion of the transaction, the chief executive officer directly owned 537,540 shares of the company’s stock, valued at approximately $49,459,055.40. This represents a 2.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott Burrows sold 7,500 shares of the company’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $91.83, for a total transaction of $688,725.00. Following the completion of the transaction, the chief financial officer directly owned 79,762 shares of the company’s stock, valued at approximately $7,324,544.46. The trade was a 8.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 138,064 shares of company stock valued at $12,349,518. 15.69% of the stock is owned by corporate insiders.

Spyre Therapeutics Company Profile

(Free Report)

Spyre Therapeutics is a clinical-stage biotechnology company developing antibody-based medicines for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Its research focuses on therapies designed to target immune pathways involved in these conditions. The company’s pipeline includes investigational antibodies targeting TL1A, IL-23 and integrin α4β7, as well as potential combinations of these approaches. Spyre has no approved products, and its candidates remain in development.

Read More

Institutional Ownership by Quarter for Spyre Therapeutics (NASDAQ:SYRE)

Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.